Ruxolitinib and autoimmune diseases
What is it about?
Highlighting the intimate relationship between auto-inflammatory diseases and myeloproliferative neoplasia and demonstrating the dual-acting properties of JAK-inhibition: Myelosuppression and anti-inflammation.
Why is it important?
The potent anti-inflammatory properties of ruxolitinib make JAK-inhibitors a therapeutic option when treating non-malignant inflammatory diseases. This was most recently demonstrated by the effect on Graft-versus-Host-disease post transplant (both acute and chronic) where ruxolitinib "rescues" a significant proportion of corticosteroid-resistant cases, but has demonstrated efficacy in psoriasis (in a topical form).
The following have contributed to this page: Mr Mads E Bjørn
In partnership with: